AB
MAZE

Amalgamated Bank’s Maze Therapeutics MAZE Stock Holding History

Amalgamated Bank’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-674
Closed -$28K – 2917
2025
Q4 		$28K Buy
674
+369
+121% +$12.7K ﹤0.01% 1994
2025
Q3 		$8K Hold
305
– – ﹤0.01% 2586
2025
Q2 		$4K Hold
305
– – ﹤0.01% 2894
2025
Q1 		$3K Buy
+305
New +$3.67K ﹤0.01% 2819

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Amalgamated Bank's MAZE Position: Q1 2026 in Review

Amalgamated Bank sold out of Maze Therapeutics (MAZE) in Q1 2026, closing a stake of 674 shares — an estimated $28K sold.

Amalgamated Bank first reported a position in MAZE in Q1 2025 and held it in 4 quarters. The position peaked at $28K in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Amalgamated Bank reported no remaining Maze Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 674 Maze Therapeutics shares in Q1 2026, an estimated $28K.
  • Amalgamated Bank first reported a position in Maze Therapeutics in Q1 2025 and held it in 4 quarters.
  • Amalgamated Bank's Maze Therapeutics position peaked at $28K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.